Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 346Neoplasms 247Prostatic Neoplasms 198Colorectal Neoplasms 151Lung Neoplasms 130Carcinoma, Non-Small-Cell Lung 108Leukemia, Myeloid, Acute 107Pancreatic Neoplasms 98Multiple Myeloma 89Glioblastoma 77Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Brain Neoplasms 73Head and Neck Neoplasms 72Carcinoma, Hepatocellular 67Squamous Cell Carcinoma of Head and Neck 65Melanoma 62Uterine Cervical Neoplasms 61Ovarian Neoplasms 59Neoplasm Metastasis 55Rectal Neoplasms 52Hematologic Neoplasms 50Recurrence 48Stomach Neoplasms 47Glioma 46Myelodysplastic Syndromes 45Motor Activity 45Triple Negative Breast Neoplasms 44Carcinoma, Renal Cell 44Endometrial Neoplasms 43Sarcoma 41

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Sensitive Prostate Cancer × 30 days × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡